Loading
AB
Avid Bioservices, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Jan 2024.
Avid Bioservices, Inc.: what insiders have been doing
Avid Bioservices, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Avid Bioservices, Inc. in twelve months, the latest record being from 7 February 2025.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
229
Thresholds
n/a
Buy Volume
€365,956
2 ops. · all time
Sell Volume
€4M
53 ops. · all time
Who traded when
BuySaleNicholas Stewart Green1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended April 2024 · cache
Income statement
RevenueUS$120.5M
Gross profitUS$6.3M5% margin
Net income-US$121.2M-100.6% margin
Last declaration on 7 February 2025
Declarations229 total
124,191 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000857:0
45,611 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000863:0
37,746 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000854:0
36,368 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000862:0
49,535 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000861:0
50,796 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000859:0
43,379 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000860:0
112,735 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000858:0
159,375 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000856:0
66,799 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000864:0
130,324 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000855:0
20,128 shares0Common Stock, $0.001 par valueSEC:0001683168-25-000585:0
5,507 sharesCommon Stock, $0.001 par valueSEC:0001683168-25-000297:0
1,755 shares@ US$6.0520.5% of flowCommon Stock, $0.001 par valueSEC:0001683168-25-000033:0
1,755 shares@ US$6.0523.2% of flowCommon Stock, $0.001 par valueSEC:0001683168-25-000034:0
1,755 shares@ US$6.05211.1% of flowCommon Stock, $0.001 par valueSEC:0001683168-25-000035:0
10,695 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-009026:0
119,973 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-009023:0
9,300 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-009025:0
4,279 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-009024:0
75,000 shares@ US$12.312240.5% of flowCommon Stock, $0.001 par valueSEC:0001683168-24-008985:0
26,756 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-008800:0
26,756 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-008803:0
26,756 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-008801:0
26,756 sharesCommon Stock, $0.001 par valueSEC:0001683168-24-008805:0
25 of 229 declarations
About Avid Bioservices, Inc.
Avid Bioservices, Inc. (ticker: CDMO) is a United States-based biologics contract development and manufacturing organization (CDMO) focused on mammalian protein development and CGMP manufacturing. For investors, it sits in the healthcare/pharma supply-chain segment and is quoted on the NASDAQ market in the United States. The company’s core proposition is to help biotechnology and pharmaceutical clients move biologic programs from early development through clinical supply and commercial manufacturing, with an emphasis on process development, analytical development, technology transfer, and reliable contract manufacturing. ([avidbio.com](https://avidbio.com/company/?utm_source=openai))
Avid’s roots go back to 1993, when biologics activity began within Peregrine Pharmaceuticals. The Avid Bioservices subsidiary was formed in 2002, the first manufacturing client was signed in 2003, and the company received its first FDA commercial approval in 2005. In 2018, Avid became a dedicated independent biologics manufacturer. A major corporate milestone followed in 2025, when the company was acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction, taking Avid private and setting the stage for a new growth phase. ([avidbio.com](https://avidbio.com/company/?utm_source=openai))
Read moreShow less
Operationally, Avid positions itself as a full-lifecycle partner for mammalian protein biologics. Its service portfolio includes cell line development, upstream and downstream process development, analytical method development and qualification, early-phase support, CGMP clinical manufacturing, and commercial-scale drug substance production. The company highlights more than 30 years of experience, more than 600 batches produced, more than 325 clinical batches, more than 275 commercial batches, and more than 20,000L of single-use bioreactor capacity. It also emphasizes a strong regulatory track record, with more than 20 years of successful inspection history and approved-manufacturer status for products marketed in more than 90 countries. ([avidbio.com](https://avidbio.com/cdmo-solutions/quality-and-regulatory-services/))
From a competitive standpoint, Avid is not a broad diversified CDMO; rather, it is a niche biologics specialist. That specialization can be attractive to sponsors seeking technical depth, quality discipline, and responsive project management in a market where execution risk is high and supply continuity matters. Its facilities are located in Orange County, California, giving it proximity to a meaningful U.S. biotech hub and supporting its positioning as a domestic manufacturing partner for companies considering reshoring, supply-chain de-risking, or accelerated development timelines. ([avidbio.com](https://avidbio.com/wp-content/uploads/2023/12/Avid-Bioservices-Investor-Presentation.pdf?utm_source=openai))
Recent news suggests management is actively reinforcing commercial and operational capabilities. In January 2026, Avid appointed Rich McAvoy as Chief Business Officer to support growth strategy and execution. In February 2026, the company opened a new Early Phase Center of Excellence in Costa Mesa, a 78,000-square-foot facility designed to expand development capacity and create a smoother path from early clinical work to commercial manufacturing. In May 2026, Avid appointed Kerri McCullough Wood as Chief Commercial Officer to lead global commercial strategy across early- and late-phase programs. These developments point to a company investing in capacity, leadership, and commercial reach within the United States biologics CDMO market. ([avidbio.com](https://avidbio.com/news/avid-bioservices-appoints-rich-mcavoy-as-chief-business-officer/?utm_source=openai))
